利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.043 秒)

    Focused libraries, functional profiling, laser SELEX, and DESELEX
    2.
    发明授权
    Focused libraries, functional profiling, laser SELEX, and DESELEX 有权
    专注图书馆，功能剖析，激光SELEX和DESELEX

    公开(公告)号：US08367627B2

    公开(公告)日：2013-02-05

    申请号：US11992125

    申请日：2006-09-15

    申请人： Bruce A. Sullenger ,  Juliana M. Layzer ,  Christopher P. Rusconi ,  Sabah Oney ,  Nanette L. S. Que-Gewirth

    发明人： Bruce A. Sullenger ,  Juliana M. Layzer ,  Christopher P. Rusconi ,  Sabah Oney ,  Nanette L. S. Que-Gewirth

    IPC分类号： C07H21/02

    CPC分类号： C12N15/1048 ,  C07K14/745 ,  C12N15/111 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/13

    摘要： Focused aptamer libraries are constructed in accordance with a proteome (i.e., complex mixture of native biomolecules). The libraries may be screened to identify one or more candidate aptamers with desired biological activities other than specific binding to a target. Aptamers which are selected or derivatives thereof may be used for those specific activities in biological systems. Any combination of deconvoluting a focused library (functional profiling), increasing frequencies of particular aptamers in a focused library (Laser SELEX), and decreasing frequencies of particular aptamers in a focused library (DeSELEX) may be performed prior to assaying biological activity.

    摘要翻译： 根据蛋白质组（即天然生物分子的复杂混合物）构建聚焦的适体文库。 可以筛选文库以鉴定具有除特异性结合靶标以外的所需生物活性的一种或多种候选适体。 选择的适体或其衍生物可用于生物系统中的那些特定活性。 在分析生物活性之前，可以进行解卷积聚焦库（功能分析），聚焦库（Laser SELEX）中特定适体的频率增加以及聚焦文库（DeSELEX）中特定适体的频率降低的任何组合。

    Modulators of pharmacological agents
    6.
    发明授权
    Modulators of pharmacological agents 有权
    药理调节剂

    公开(公告)号：US07300922B2

    公开(公告)日：2007-11-27

    申请号：US10155233

    申请日：2002-05-28

    申请人： Bruce A. Sullenger ,  Christopher P Rusconi

    发明人： Bruce A. Sullenger ,  Christopher P Rusconi

    IPC分类号： A61K31/70 ,  C07H21/04 ,  C12N15/00 ,  A61K35/14

    CPC分类号： C12N15/1137 ,  C12N15/113 ,  C12N15/115 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3515 ,  C12Y304/21022 ,  C12N2310/3521

    摘要： The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.

    摘要翻译： 核酸配体的生物活性在体内被调节（即增强或抑制）以产生所需的生物效应。 这通过施用调节剂或调节剂来实现，该调节剂或调节剂改变核酸配体对其靶的结合，或者在配体仍然发挥作用的同时降解或以其它方式切割，代谢或分解核酸配体。 本发明的调节剂可以根据各种因素，包括患者的进展以及医师在如何达到最佳治疗方面的酌处权，根据需要实时施用。 因此，本发明在核酸配体治疗过程中首次提供可调节的治疗方案。

    Modulators of pharmacological agents
    8.
    发明授权
    Modulators of pharmacological agents 有权
    药理调节剂

    公开(公告)号：US08283330B2

    公开(公告)日：2012-10-09

    申请号：US12637467

    申请日：2009-12-14

    申请人： Bruce A. Sullenger ,  Christopher P Rusconi

    发明人： Bruce A. Sullenger ,  Christopher P Rusconi

    IPC分类号： A61K31/70 ,  C07H21/04

    CPC分类号： C12N15/1137 ,  C12N15/113 ,  C12N15/115 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3515 ,  C12Y304/21022 ,  C12N2310/3521

    摘要： The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.

    摘要翻译： 核酸配体的生物活性在体内被调节（即增强或抑制）以产生所需的生物效应。 这通过施用调节剂或调节剂来实现，该调节剂或调节剂改变核酸配体对其靶标的结合，或者在配体仍然发挥作用时降解或以其它方式切割，代谢或分解核酸配体。 本发明的调节剂可以根据各种因素，包括患者的进展以及医师在如何达到最佳治疗方面的酌处权，根据需要实时施用。 因此，本发明在核酸配体治疗过程中首次提供可调节的治疗方案。